Utility of dual assessment of cyTRBC1 and cyTRBC2 by flow cytometry for identifying clonality in sCD3-negative to dimly expressing T cells
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
We read with great interest the article by Horna et al. entitled “Dual T-cell receptor β constant chain (TRBC) 1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry” [ 1 ], published in Blood Cancer Journal. The authors reported a newly developed and strategically engineered monoclonal antibody, JOVI.1, specifically targeting TRBC2. When combined with anti-TRBC1 antibodies, this approach effectively eliminates the spurious TRBC1-dim signal observed in single-color staining assays, thereby enabling accurate identification of clonal T-cell populations and providing robust support for clinical applications in detecting aberrant T-cell clones. However, we have certain reservations regarding the interpretation of the authors’ findings and would like to present complementary data to further enrich the discussion on this subject. In their study, Horna et al. demonstrated that cytoplasmic (cy) TRBC1 and cyTRBC2 staining, as assessed by flow cytometry, can be used to detect TRBC polytypia in benign immature T-cell precursors, particularly within the CD4/CD8 double-positive and single-positive subsets [ 1 ]. However, the applicability of this approach to CD4/CD8 double-negative precursor populations remains unexplored. Furthermore, in the analysis of cyTRBC1 and cyTRBC2 expression in nine patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) [ 1 ], it was not specified whether all cases originated from CD4/CD8 double-positive or single-positive thymic precursors, nor was it clarified whether the assessment of cyTRBC1 and cyTRBC2 expression is applicable across all immunophenotypic subtypes of T-ALL/LBL. Additionally, both the T-ALL/LBL and surface (s) CD3-negative T-cell neoplasm cohorts were limited by small sample sizes-only nine cases in each group-underscoring the necessity for further validation through larger cohort studies. In our previous study, using cyTRBC1-based assessment by flow cytometry, we identified a novel subset of sCD3-negative T-cell clones of uncertain significance (T-CUS) in individuals without overt T-cell malignancy [ 2 ]. This subset, characterized by small clone size, displayed an immunophenotype defined by sCD3-cyCD3 + CD4+ expression, closely resembling that observed in certain T-cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL). Although Horna et al. confirmed the utility of sTRBC1 and sTRBC2 in detecting clonality among sCD3-positive T-CUS, no study to date has reported the expression patterns of cyTRBC1 and cyTRBC2 in sCD3-negative T-CUS. To address these gaps, we conducted an expanded cohort study comprising 15 patients with T-ALL/LBL, 28 with sCD3-negative T-cell neoplasms, and 7 with sCD3-negative T-CUS, aiming to validate the diagnostic value of cyTRBC1 and cyTRBC2 in assessing clonality within sCD3-dim or negative T-cell populations. Specimens, including peripheral blood, bone marrow, lymph node biopsy, mass needle biopsy, hydrothorax, ascites, and cerebrospinal fluid, were received for diagnostic flow cytometric analysis at Department of Laboratory Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, between March 2025 and November 2025. Electronic medical records, including clinical data, pathology reports, and other laboratory data, were retrospectively reviewed. This study was reviewed and approved by the Ethics Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital. All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all individual participants (or their legal guardians) included in the study. Abnormal or suspicious sCD3-negative or dim T cell subsets were identified based on the expression profiles of sCD3, CD2, CD5, CD7, CD4, CD8, CD16, and CD56, as previously described [ 2 ]. These subsets were subsequently subjected to further immunophenotypic characterization, including assessment of cyTRBC1 (PE-conjugated, JOVI.1), cyTRBC2 (APC-conjugated, SAM.2), and cyCD3. Additional markers evaluated included TdT, CD34, CD1a, TCRγδ, CD57, CD10, PD-1, CD45RA, and CD45RO to support comprehensive phenotypic classification. All fluorochrome-conjugated antibodies were obtained from Beckman Coulter (Beckman Coulter, Brea, CA), with detailed information provided in Supplementary Table S1 . Intracellular staining was performed using the BC IntraPrep Permeabilization Reagent Kit. Flow cytometric data were acquired on a BC Navios flow cytometer and analyzed using Kaluza software (version 2.1). A minimum of 100 clustered events was required to define a distinct cell population. Monotypic expression pattern was defined as equivalent TRBC2:TRBC1 ratios (TRBC2:TRBC1 < 0.18 or >5.7) [ 1 ]. To investigate the expression patterns of cyTRBC1 and cyTRBC2 across different immunophenotypic subtypes of T-ALL/LBL, we analyzed eighteen samples from fifteen patients, including four with early T-cell precursor ALL/LBL, two with pro-T-ALL/LBL, three with pre-T-ALL/LBL, and six with cortical T-ALL/LBL (Table 1 ). All cortical T-ALL/LBL cases exhibited co-expression of CD4 and CD8, whereas the remaining subtypes were negative for both markers (Supplementary Table S2 ). Table 1 Clinical characteristics of patients with T-ALL/LBL, sCD3-negative T-cell neoplasms and sCD3-negative TCUS. Full size table Monotypic expression of either cyTRBC1 or cyTRBC2 was observed in eight of fifteen patients (53.0%) with T-ALL/LBL (Supplementary Table S2 ). Of these eight cases, six (75.0%) exhibited cyTRBC2 expression, and two (25.0%) exhibited cyTRBC1 expression, indicating a preferential expression pattern favoring cyTRBC2. Notably, all six patients with cortical T-ALL/LBL exhibited monotypic expression of cyTRBC1 or cyTRBC2 (Fig. 1A ). These findings support the utility of these markers in assessing clonality within T-cell precursors at the double-positive stage. Fig. 1: Immunophenotypes and cyTRBC expression in patients with T-ALL/LBL, sCD3-negative T-cell neoplasms, sCD3-negative T-CUS. Full size image A Flow cytometry of bone marrow from a patient with cortical T-ALL/LBL revealed bright expression of cyTRBC1 (red), with a cyTRBC1/cyTRBC2 ratio of 147. B Flow cytometry of peripheral blood from a patient with early T-cell precursor ALL/LBL showed a monotypic expression pattern of cyTRBC2 (red), with a cyTRBC1/cyTRBC2 ratio of 0.004. C Flow cytometry of an axillary lymph node biopsy from a patient with pre-T-ALL/LBL demonstrated negative expression for both cyTRBC1 and cyTRBC2 (red). D Flow cytometry of a cervical lymph node biopsy from a patient with ALK-positive anaplastic large cell lymphoma exhibited monotypic expression of cyTRBC1 (red), with a cyTRBC1/cyTRBC2 ratio of 445. E Flow cytometry of cerebrospinal fluid from a patient with monomorphic epitheliotropic intestinal T-cell lymphoma showed monotypic expression of cyTRBC2 (red), with a cyTRBC1/cyTRBC2 ratio of 0.01. F Flow cytometry of hydrothorax fluid from a patient with AITL revealed partial expression of cyTRBC2 (red), with a cyTRBC1/cyTRBC2 ratio of 0.005. G Flow cytometry of a cervical lymph node biopsy from a patient with peripheral T-cell lymphoma, not otherwise specified, exhibited negative expression for both cyTRBC1 and cyTRBC2 (red). H Flow cytometry of bone marrow from a patient diagnosed with septicopyemia showed sCD3-negative T-CUS subset (red) displaying monotypic expression of cyTRBC2, with a cyTRBC1/cyTRBC2 ratio of 0.01. I Flow cytometry of a cervical lymph node biopsy from a patient with hemophagocytic lymphohistiocytosis demonstrated a sCD3-negative T-CUS subset (red) exhibiting partial expression of cyTRBC2, with a cyTRBC1/cyTRBC2 ratio of 0.004. J Flow cytometry of peripheral blood from a patient with anemia showed a sCD3-negative T-CUS subset (red) with double-negative for both cyTRBC1 and cyTRBC2. Furthermore, monotypic cyTRBC2 expression was observed in two out of nine patients (22.2%) with CD4/CD8 double-negative T-ALL/LBL (Supplementary Table S2 ), including one case of early T-cell precursor ALL/LBL (Fig. 1B ) and one case of pro-T-ALL/LBL. The remaining cases (77.8%, 7/9) showed no detectable expression of either cyTRBC1 or cyTRBC2 (Fig. 1C , Supplementary Table S2 ). Notably, monotypic expression of cyTRBC1 was not identified in any of the cases. Although on previous studies [ 3 , 4 ] using cytoplasmic TRBC1 staining only, 80-90% of CD4/CD8 double-negative T-ALL/LBL cases were reportedly negative for cyTRBC1, which suggests potential expression of cyTRBC2. In our study, by simultaneously assessing TRBC1 and TRBC2 expression, we observed that 77.8% (7/9) of cyTRBC1-negative cases were negative for both cyTRBC1 and cyTRBC2. Given that in CD4/CD8 double-negative T-cell blasts, the TRD, TRG, and TRB loci undergo rearrangement, resulting in the formation of either a TCRγδ receptor or a pre-TCR, which guides development towards the γδ or αβ T-cell lineage, respectively. Signaling via the pre-TCR facilitates passage through the β-selection checkpoint and advancement to the CD4/CD8 double-positive stage. Subsequently, TRA rearrangement takes place to assemble a complete TCRαβ receptor [ 5 , 6 , 7 ]. In our study, the detectable monotypic expression of cyTRBC in a subgroup of CD4/CD8 double-negative T-ALL/LBL cases gives rise to a hypothesis that the JOVI.1 and SAM.2 antibodies are capable of recognizing TCRβ chains within pre-TCR complexes in double-negative T-cell precursors that have undergone TCRB rearrangement. Furthermore, the frequent absence of cyTRBC1 and cyTRBC2 expression in these cases indicates that the detection of cyTRBC is not appropriate for very early-stage T-cell precursors prior to TCRB rearrangement. To verify the expression patterns of cyTRBC1 and cyTRBC2 in patients with sCD3-negative T-cell neoplasms, we analyzed 35 samples from 28 patients (Table 1 ). The cohort included sixteen patients with AITL, seven with peripheral T-cell lymphoma, not otherwise specified, two with monomorphic epitheliotropic intestinal T-cell lymphoma, one with ALK-positive anaplastic large cell lymphoma, one with AITL with diffuse large B-cell lymphoma, and one with lymphocyte-variant hypereosinophilic syndrome. Immunophenotypically, the neoplastic cells expressed CD8 in three patients. One case was negative for both CD4 and CD8. The remaining sCD3-negative T-cell neoplasms exhibited CD4 positivity. Monotypic expression of cyTRBC1 and cyTRBC2 was observed in 3 patients (10.7%, 3/28) (Fig. 1D ) and 19 patients (67.9%, 19/28) (Fig. 1E, F ), respectively. The remaining 6 patients (21.4%) showed negativity for both cyTRBC1 and cyTRBC2 (Fig. 1G , Supplementary Table S2 ). These findings align with our previous study [ 2 ], in which approximately 88% of CD3-negative lymphomas were negative for cyTRBC1 and were hypothesized to express cyTRBC2. The current study further confirms that combined evaluation of cyTRBC1 and cyTRBC2 enables the identification of a subset of cases lacking both markers, thereby providing a more comprehensive immunophenotypic profile than cyTRBC1 staining alone. Additionally, in comparison with the cohorts reported by Horna et al. [ 1 ] and those in previous studies [ 8 , 9 ], our cohort demonstrated a tendency towards a lower frequency of cyTRBC1 expression (10.7% versus 23–50%) and a higher proportion of cyTRBC1 and cyTRBC2 double-negative cases (21.4% versus 13%). Nevertheless, these findings necessitate further validation in studies with a larger sample size. In addition, we evaluated the expression patterns of cyTRBC1 and cyTRBC2 in nine samples from seven patients with sCD3-negative T-CUS, in the absence of evidence indicating T-cell lymphoma (Table 1 ). The underlying clinical conditions in these patients included infection ( n = 3), anemia ( n = 1), B-cell lymphoma ( n = 1), hemophagocytic lymphohistiocytosis ( n = 1), and acute myeloid leukemia ( n = 1). Consistent with our previous findings [ 2 ], all patients with sCD3-negative T-CUS demonstrated the immunophenotypic profile sCD3-/cyCD3 + /CD4 + /CD8-. Monotypic expression of cyTRBC2 was observed in five out of seven patients (71.4%) (Fig. 1H, I ), while the remaining two patients (28.6%) showed negativity for both cyTRBC1 and cyTRBC2 (Fig. 1J ). Notably, none of the sCD3-negative T-CUS patients exhibited cyTRBC1 positivity (Supplementary Table S2 ). These findings further support the preferential expression of cyTRBC2 [ 8 ], a pattern consistent with that observed in sCD3-negative T-cell neoplasms, thereby reinforcing the clonal nature of these T-cell expansions [ 10 , 11 ]. Moreover, the assessment of cyTRBC1 and cyTRBC2 expression may serve as a valuable tool for the identification and monitoring of the sCD3-negative T-CUS population. In summary, this study demonstrates that the combined assessment of cyTRBC1 and cyTRBC2 via flow cytometry represents a reliable approach for evaluating clonality in CD4/CD8 double-positive T-ALL/LBL, sCD3-negative mature T-cell neoplasms, and sCD3-negative T-CUS. It also identifies limitations when applied to the very early stages of CD4/CD8 double-negative T-ALL/LBL, prior to TCRB rearrangement. In addition, we provide the first report on cyTRBC expression in sCD3-negative T-CUS, demonstrating a high prevalence of monotypic cyTRBC2 expression in these cases.
Fields of Study & Subjects
Acute Lymphoblastic Leukemia research
T-cell and B-cell Immunology
Lymphoma Diagnosis and Treatment
Publication details
- Journal / source
- Blood Cancer Journal
- Volume
- 16
- Issue
- 1
- Pages
- 46
- Publication date
- 31 March 2026
- Language
- EN